Diagnostic Criteria for Chronic Pancreatitis
The diagnosis of chronic pancreatitis requires at least two of the following: characteristic imaging findings (ductal changes, calcifications, parenchymal abnormalities), evidence of exocrine pancreatic insufficiency, or histological confirmation of irreversible pancreatic damage. 1
Imaging-Based Diagnosis (Primary Approach)
Advanced Disease
For patients with suspected chronic pancreatitis and advanced morphological changes:
- CT scan is the initial imaging modality of choice 2
- Detects calcifications, ductal dilation, and parenchymal atrophy
- Sensitivity approximately 60% for early disease but excellent for advanced disease 2
- Useful for excluding pancreatic malignancy
Early/Mild Disease
When CT is negative or equivocal but clinical suspicion remains high:
EUS (Endoscopic Ultrasound) is the preferred test 3
- Sensitivity: 68-100% with specificity: 78-97% 2
- Uses standardized scoring (Rosemont criteria with major and minor features) 4
- Major criteria: hyperechoic foci with shadowing, main pancreatic duct calculi, lobularity with honeycombing 4
- Minor criteria: cysts, dilated ducts ≥3.5mm, irregular duct contour, hyperechoic duct wall, strands 4
- Detects mild parenchymal and ductal abnormalities not visible on CT 2
MRI/MRCP (with secretin enhancement) is a complementary alternative 3
Critical caveat: Subtle EUS findings may lack clinical relevance—the Rosemont criteria are more stringent than conventional criteria to reduce false positives 5
Functional Testing (Supportive Evidence)
Non-Invasive Pancreatic Function Tests
Faecal elastase-1 is the preferred non-invasive test 2:
- Normal values: 200-500 μg/g
- Mild-moderate insufficiency: 100-200 μg/g
- Severe insufficiency: <100 μg/g
- Sensitivity: 73-100% for moderate-to-severe disease 2
- Major limitation: Poor sensitivity (<60%) in mild/early disease 2
- Unaffected by enzyme replacement therapy or diet 2
Important: All non-invasive pancreatic function tests require significant loss of function (>90% pancreatic destruction) before becoming positive 2, 6
Invasive Pancreatic Function Tests
Not recommended in UK/European practice 2—difficult to perform, lack standardization, and data are decades old. American guidelines still mention them, but they have no practical role in current clinical practice.
Diagnostic Algorithm (STEP-wise Approach)
The American Pancreatic Association recommends a STEP algorithm (Survey, Tomography, Endoscopy, Pancreas function testing) 1:
- Clinical assessment: Abdominal pain pattern, risk factors (alcohol, smoking, family history)
- Initial imaging: CT scan for suspected advanced disease
- Advanced imaging: EUS or MRCP-S if CT negative/equivocal but suspicion remains high
- Functional testing: Faecal elastase-1 to assess exocrine insufficiency (only useful if moderate-severe disease)
- Histology: Gold standard but rarely obtained outside surgical specimens
Classification Once Diagnosed
After establishing diagnosis, characterize patients using:
- TIGAR-O etiology (Toxic, Idiopathic, Genetic, Autoimmune, Recurrent, Obstructive) 1
- Morphology (Cambridge criteria for ductal changes)
- Physiologic state (exocrine and endocrine function) 1
Screening for Diabetes
Screen for diabetes within 3-6 months following acute pancreatitis, then annually thereafter 7. For established chronic pancreatitis, annual diabetes screening is recommended 7. Consider screening for exocrine pancreatic insufficiency (faecal elastase) concurrently, as both often coexist 7.
Common Pitfalls
- Do not rely on ultrasound alone—sensitivity only ~60% for chronic pancreatitis 2
- Do not use A1C to screen for pancreatogenic diabetes—low sensitivity 7
- Avoid over-interpreting subtle EUS findings in patients with pain alone—may lead to false-positive diagnoses 2
- Do not pursue invasive pancreatic function tests—obsolete in modern practice 2
- Remember that early chronic pancreatitis may be reversible—particularly autoimmune and obstructive forms 8